C
Christopher S. Williams
Researcher at Vanderbilt University
Publications - 177
Citations - 12251
Christopher S. Williams is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Colitis & Cancer. The author has an hindex of 41, co-authored 149 publications receiving 11139 citations. Previous affiliations of Christopher S. Williams include Beaumont Hospital & McGill University.
Papers
More filters
Journal ArticleDOI
Molecular basis of human hypertension: Role of angiotensinogen
Xavier Jeunemaitre,Florent Soubrier,Yuri Kotelevtsev,Richard P. Lifton,Richard P. Lifton,Christopher S. Williams,Anne Charru,Steven C. Hunt,Paul N. Hopkins,Roger R. Williams,Jean Marc Lalouel,Pierre Corvol +11 more
TL;DR: Evidence of genetic linkage between the angiotensinogen gene (AGT) and hypertension is obtained, association of AGT molecular variants with the disease is demonstrated, and significant differences in plasma concentrations of angiotENSinogen among hypertensive subjects with different AGT genotypes are found.
Journal ArticleDOI
The role of cyclooxygenases in inflammation, cancer, and development
TL;DR: Offspring from cox-2 null by ApcΔ716 matings exhibit an 86% reduction in polyp number when compared to offspring from control animals, thus providing genetic evidence that COX-2 contributes to tumor formation or growth.
Journal ArticleDOI
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis
Matthew D. Rutter,Brian Saunders,Kay H. Wilkinson,Steve Rumbles,Gillian Schofield,Michael A. Kamm,Christopher S. Williams,Ashley B. Price,Ian C. Talbot,Alastair Forbes +9 more
TL;DR: In long-standing extensive ulcerative colitis, the severity of colonic inflammation is an important determinant of the risk of colorectal neoplasia and endoscopic and histological grading of inflammation could allow better risk stratification for surveillance programs.
Journal ArticleDOI
Host cyclooxygenase-2 modulates carcinoma growth
TL;DR: It was found that tumor growth was markedly attenuated inCOX-2(-/-), but not COX-1(-/-) or wild- type mice, and treatment of wild-type C57BL/6 mice bearing LLC tumors with a selective COX -2 inhibitor reduced tumor growth.
Journal ArticleDOI
A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro.
Ituro Inoue,T Nakajima,Christopher S. Williams,J Quackenbush,R Puryear,M Powers,T Cheng,E H Ludwig,Arya M. Sharma,Akira Hata,Xavier Jeunemaitre,Jean-Marc Lalouel +11 more
TL;DR: A common variant in the proximal promoter, the presence of an adenine, instead of a guanine, 6 bp upstream from the initiation site of transcription, in significant association with the disorder.